Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Q2 FY23 Earnings Presentation
31 slides from Iol Chemicals & Pharmaceuticals's earnings presentation, November 2022
Slide 1: Q2FY23 Investor Presentation November 2022
IOL Chemicals And Pharmaceuticals Limited Q2FY23 Investor Presentation November 2022
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by IOL Chemicals & Pharmaceuticals Limited (the “Companies”, IOL) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on i
Slide 3: Table of Contents
Table of Contents 01 IOLCP at a glance 02 Financial Highlights 03 Company Overview Quarterly Income Statement Milestones About IOL Chemicals and Pharmaceuticals Ltd. Half yearly Income statement Core management team Quarterly performance highlights Annual Income Statement Board of Directors Segmenta
Slide 4: About IOL Chemicals and Pharmaceuticals Limited
About IOL Chemicals and Pharmaceuticals Limited Incorporated in 1986, IOLCP is one of the leading Pharmaceuticals company and is a significant player in the field of specialty chemicals with world class facilities Team size of 2300+ employees Credit Rating: A+, outlook; stable (Care Ratings Limited)
Slide 5: Executive Director & CEO Message
Executive Director & CEO Message Dr. Sanjay Chaturvedi, Executive Director & CEO The global economy is going through a roller-coaster ride as central banks battle inflation through rate hikes. Apart from inflation, the global trade and investor sentiments are also impacted by uncertainty over Russia
Slide 6: Quarterly performance highlights
Quarterly performance highlights Operational Highlights Q2FY23 Financial Performance INR 546.5 Cr. INR 36.7 Cr. 6.7 % Revenues EBITDA EBITDA Margin Received REACH certification, regulatory approval from the European Union for the supply INR 15.7 Cr. 2.9 % of ethyl acetate PAT Margin Profit After T
Slide 7: Segmental highlights
Segmental highlights Chemical Segment Pharmaceutical Segment Operating Revenue net intersegment (Rs. crore) Chemical Operating Revenue (Rs. crore) 350 segment has 350.0 303 302 302 300 297 276 279 been impacted 285 258 300 300.0 238 due to volatility 241 250 250.0 213 200 in raw material 200.0 150 p
Slide 8: Geographical & segmental break-up
Geographical & segmental break-up Geographical Break-up (Rs. crore) Segmental Revenue (Rs. crore) 2000 25% 36% 38% 34% 31% 26% 1222 1172 1179 1638 1121 1600 1008 1355 1250 799 1200 1038 679 624 588 818 556 517 800 633 647 645 613 546 354 400 350 289 0 FY18 FY19 FY20 FY21 FY22 H1FY23 FY18 FY19 FY20 F
Slide 9: Financial Overview
FINANCIAL OVERVIEW
Slide 10: Quarterly income statement
Quarterly income statement Particulars (Rs. Cr) Q2 FY23 Q2 FY22 YoY Q1 FY23 QoQ Revenues 541.4 537.9 0.7% 565.0 -4.2% Other Income 5.1 10.5 5.2 Total Income 546.5 548.4 570.2 Total Expenses 509.7 494.1 509.0 EBITDA 36.7 54.3 -32.4% 61.2 -40.0% EBITDA Margin (%) 6.7% 10.1% 10.8% Depreciation 11.32 10
Slide 11: Half-yearly income statement
Half-yearly income statement Particulars (Rs. Cr) H1 FY23 H1 FY22 YoY Revenues 1,106.4 1,056.4 4.7% Other Income 10.2 16.2 Total Income 1,116.6 1,072.6 Total Expenses 1,018.7 902.4 EBITDA 97.9 170.2 -42.5% EBITDA Margin (%) 8.8% 15.9% Depreciation 22.30 21.12 Finance Cost 6.89 3.66 Profit Before Exc
Slide 12: Income statement
Income statement Particulars (Rs. Cr) FY18 FY19 FY20 FY21 FY22 H1 FY23 Revenues 983.3 1,685.3 1,894.5 1,967.0 2,184.0 1,106.4 Other Income 6.3 10.4 16.0 24.3 32.0 10.2 Total Income 989.6 1,695.7 1,910.5 1,991.3 2,216.0 1,116.6 Total Expenses 863.7 1,275.7 1,320.6 1,375.2 1,927.6 1,018.7 EBITDA 125.9
Slide 13: Balance Sheet
Balance Sheet Balance Sheet (Rs. Cr) FY18 FY19 FY20 FY21 FY22 H1FY23 Shareholders' Funds 215.7 474.3 813.5 1260.4 1390.3 1440.0 Debt 421.9 284.0 56.0 0.0 0.0 0.0 Other Long Term Liabilities 33.6 20.8 79.7 59.1 56.6 56.6 Other Current Liabilities 180.9 162.8 220.6 290.6 513.4 512.4 Equity & Liabiliti
Slide 14: 5-years Performance
5-years Performance Rising input costs & surging price of imported raw materials have dented profitability Operational Revenue (Rs Cr) EBITDA (Rs Cr) and EBITDA Margin (%) PAT (Rs Cr) and PAT Margin (%) CAGR growth of 22% 30.9% 30.9% in last 4 years 22.3% 19.0% 24.8% 13.0% 14.0% 12.7% 8.8% 7.5% 4.5%
Slide 15: Product wise Segmentation
Product wise Segmentation FY18 FY22 H1FY23 1181, 362, 54% 519, 47% 37% 35, 3% 351, 241, 22% 16% 586, 652, 30% 346, 31% 60% Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's Chemicals Ibuprofen Other API's The share of non-Ibuprofen business is consistently rising with other APIs now co
Slide 16: Company Overview
COMPANY OVERVIEW
Slide 17: Milestones
Milestones 2009 - Commencement of 2019 - Unit-06 for 1996 - Commencement IBB, MCA and Acetyl Chloride 2015 - USFDA, EIR for Pantoprazole Commenced of Ethyl Acetate Plant Plants Ibuprofen (Dedicated) commercial 1999 - Commencement 2010 - Listing on NSE Co- 2016 - Unit-03 for 2020 -
Slide 18: Core management team
Core management team Varinder Gupta (Managing Director) Wide and rich experience of more than 35 years Vikas Gupta in the chemical & fertilizer industry and along (Executive Director) with a comprehensive approach and strong Academically equipped with knowledge and possesses Pharma API industry
Slide 19: Board of Directors
Board of Directors Rajender Mohan Malla (Chairman and Independent Director) With four decades of experience held top and significant decision-making positions in Banks, Financial Institutions & NBFCs Harpal Singh In his most recent executive roles, he was MD & (Independent Director) CEO of PTC I
Slide 20: Certifications and Accreditations
Certifications and Accreditations Approved USFDA facility since EUGMP Certification in 2013, Certificate of Suitability from Certified Halal in accordance 2015, recertified in 2019 2017 & Recertification in 2020 Certificate of DMF Registration EDQM with Shariah Board Guidelines From MFDS Korea Certi
Slide 21: Business Overview
BUSINESS OVERVIEW
Slide 22: Business segment – Pharmaceuticals
Business segment – Pharmaceuticals IOLCP is the largest producer of Ibuprofen with ~35% Global share and the only company worldwide being backward integrated for all Intermediates and Key Starting Material of Ibuprofen • Among the largest producer of Metformin in world Product application across var
Slide 23: Business segment – Specialty chemicals
Business segment – Specialty chemicals IOLCP first commenced manufacturing Ethyl Acetate in 1996, with a starting capacity of 3000 tonnes p.a. Today, the Company has grown this business to become the largest single location plant in India, with a production capacity of 1,00,000 tonnes p.a. • India’s
Slide 24: Manufacturing facilities
Balance Manufacturing facilities API manufactured in batch manner and Facility is coupled with ISO class-8 HVAC 1 3 5 intermediates & Specialty chemicals in Dedicated blocks involved in system, PSA Nitrogen & Purified water continuous product delivery manner manufacturing of APIs along with 127 MTPH
Slide 25: Core sustainability pillars
Core sustainability pillars Environment Social Governance Strive to minimize the adverse impact Construction and renovation of schools Implemented a sound and well- on environment, health and Safety by and provided technical equipment for structured corporate governance that upgrading technolo
Slide 26: Industry Overview
INDUSTRY OVERVIEW
Slide 27: Industry overview – Pharmaceuticals
Industry overview – Pharmaceuticals Indian Pharmaceutical Export Market-API World Pharmaceutical Industry • The growth of the sector is fueled by the adoption of global standards and the establishment of large-scale $1.4 operations in the country. India has the biggest number of US FDA-approved plan
Slide 28: Industry overview – Specialty Chemicals
Industry overview – Specialty Chemicals • India’s chemical sector is witnessing transformative shift, driven by the availability of low-cost labor as well as a global phenomenon of China plus one strategy that attempts to focus on development of alternative supply-chain market for the sector apart f
Slide 29: Way Forward
WAY FORWARD
Slide 30: Way forward
Way forward Four pronged strategy for growth Capacity Improved Focus on Expanding Regulated expansion in asset Non-Ibuprofen Markets Pharma & utilization Business Chemicals Focus on efficiently utilizing Plan to enhance our product Target non- Ibuprofen business Capacity expansion for existing asset
Slide 31: Thank You
Thank You Company : Investor Relations Advisors : IOL Chemicals & Adfactorspr Pvt. Ltd. Pharmaceuticals Ltd. Mr. Pardeep Kumar Khanna, Snighter Albuquerque CFO snighter.a@adfactorspr.com pardeepkhanna@iolcp.com Darshan Mankad darshan.mankad@adfactorspr.com www.iolcp.com www.adfactorspr.com
IOL Chemicals and Pharmaceuticals — Q2 FY23 Earnings Presentation on 6ix